Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Saint Luke's Roosevelt Hospital Center - Roosevelt Division
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Saint Luke's Roosevelt Hospital Center - Roosevelt Division
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Weill Medical College of Cornell University
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
University of Connecticut
mi
from
Farmington, CT
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
University of Connecticut
mi
from
Farmington, CT
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic - Weston
mi
from
Weston, FL
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic - Weston
mi
from
Weston, FL
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Mount Sinai Hosp
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Montefiore Medical Center-Einstein Campus
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Montefiore Medical Center-Einstein Campus
mi
from
The Bronx, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Montefiore Medical Center-Weiler Hospital
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Montefiore Medical Center-Weiler Hospital
mi
from
The Bronx, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Eastchester Center for Cancer Care
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Eastchester Center for Cancer Care
mi
from
The Bronx, NY
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
Delaware/Christiana Care NCORP
mi
from
Newark, DE
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
Delaware/Christiana Care NCORP
mi
from
Newark, DE
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
Heartland NCORP
mi
from
Decatur, IL
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
Heartland NCORP
mi
from
Decatur, IL
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
University of Rochester
mi
from
Rochester, NY
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
Columbus NCORP
mi
from
Columbus, OH
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
Columbus NCORP
mi
from
Columbus, OH
Click here to add this to my saved trials
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated:  10/4/2017
Dayton Oncology Research Program
mi
from
Dayton, OH
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis
Status: Enrolling
Updated: 10/4/2017
Dayton Oncology Research Program
mi
from
Dayton, OH
Click here to add this to my saved trials
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery
Status: Enrolling
Updated:  10/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery
Status: Enrolling
Updated: 10/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Northwestern
mi
from
Chicago, IL
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Northwestern
mi
from
Chicago, IL
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Hurley Medical Center
mi
from
Flint, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Lemmon-Holton Cancer Center
mi
from
Grand Rapids, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Lemmon-Holton Cancer Center
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Breslin Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Sparrow Cancer Center
mi
from
Lansing, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Sparrow Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
St Joseph Mercy Oakland Hospital
mi
from
Pontiac, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
St Joseph Mercy Oakland Hospital
mi
from
Pontiac, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
Beaumont Hospital
mi
from
Royal Oak, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
St. Johns Providence
mi
from
Warren, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
St. Johns Providence
mi
from
Warren, MI
Click here to add this to my saved trials
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated:  10/5/2017
McLaren Macomb
mi
from
Mount Clemens, MI
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Status: Enrolling
Updated: 10/5/2017
McLaren Macomb
mi
from
Mount Clemens, MI
Click here to add this to my saved trials
Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment
Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment
Status: Enrolling
Updated:  10/5/2017
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment
Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment
Status: Enrolling
Updated: 10/5/2017
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
Click here to add this to my saved trials
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
Allogeneic Breast Protocol 2: Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
Allogeneic Breast Protocol 2: Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Breast Health Education for Underserved Latino Women
A Cross Sectional Study of a Breast Health Education Program for Under-served Latino Women in Union and Mecklenburg County
Status: Enrolling
Updated:  10/6/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Breast Health Education for Underserved Latino Women
A Cross Sectional Study of a Breast Health Education Program for Under-served Latino Women in Union and Mecklenburg County
Status: Enrolling
Updated: 10/6/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
Status: Enrolling
Updated:  10/9/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
Status: Enrolling
Updated: 10/9/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Boulder Community Hospital
mi
from
Boulder, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Rose Medical Center
mi
from
Denver, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Porter Adventist Hospital
mi
from
Denver, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Swedish Medical Center
mi
from
Englewood, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Poudre Valley Hospital
mi
from
Fort Collins, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
North Colorado Medical Center
mi
from
Greeley, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
McKee Medical Center
mi
from
Loveland, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated:  10/10/2017
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Enrolling
Updated: 10/10/2017
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials